top of page

Proposed IRA Expansion Would Cripple Biopharma, Lead to Fewer Drugs: Report

The proposed expansion to the Inflation Reduction Act would substantially harm U.S. biopharma, triggering hundreds of thousands of job cuts across the industry and leading to fewer innovative treatments in critical therapeutic areas, according to a new report released Thursday by healthcare consultancy Vital Transformation.


bottom of page